Nan-Jing Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nan-Jing Peng has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Ko-Han Lin
Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei
2 shared publicationsLien-Hsin Hu
Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei
2 shared publications- Skye Hsin-Hsien Yeh
School of Medicine, National Defense Medical Center
2 shared publications Tse-Hao Lee
Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei
2 shared publications- Tsung-Hsun Yu
Brain Research Center, National Yang Ming Chaio Tung University, Taipei 112, Taiwan
2 shared publications - Wen-Sheng Huang
Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
2 shared publications
Latest Publications
- Open Access
- 4 June 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (7) , 557-567
A Landmark Multiyear Study of Alzheimer Disease: Integrating [18F]FEPPA PET Imaging With 12 Clinical Assessments for Comprehensive Disease Profiling
Purpose: This multiyear study aimed to investigate the relationship between TSPO expression and cognitive decline in Alzheimer disease (AD) using [18F]FEPPA PET imaging. We integrated this imaging data with 12 comprehensive clinical measures to assess disease severity and progression in AD, mild cognitive impairment (MCI), and healthy controls (HC). Methods: A total of 39 participants, including 17 AD patients, 9 MCI patients, and 13 healthy controls, underwent [18F]FEPPA PET imaging and neuropsychological evaluations. Quantitative analysis was performed to determine the total distribution volume (VT) ratios in 8 brain regions, such as the frontal lobe, parietal lobe, and hippocampus. Cognitive function was assessed using a battery of tests, including the Mini-Mental State Examination (MMSE), Rey Auditory Verbal Learning Test (RAVLT), and Trail Making Test. Results: AD patients exhibited significantly elevated VT ratios in the frontal lobe, parietal lobe, and hippocampus compared with HC (P < 0.01). Notably, MCI patients had higher VT ratios than both HC and AD in the temporal and occipital lobes (P < 0.05), indicating early neuroinflammatory involvement. Moderate to strong correlations (R 2 values: 0.45–0.68) were observed between TSPO expression and cognitive performance. Conclusions: The findings of this study provide preliminary support for the use of [18F]FEPPA PET in assessing neuroinflammation related to cognitive decline in AD. Moreover, our results indicate that combining imaging techniques with neuropsychological assessments may offer a useful approach for monitoring disease progression and detecting early inflammatory changes in individuals with MCI.
- 4 June 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (7) , 557-567
Open AccessA Landmark Multiyear Study of Alzheimer Disease: Integrating [18F]FEPPA PET Imaging With 12 Clinical Assessments for Comprehensive Disease Profiling
Purpose: This multiyear study aimed to investigate the relationship between TSPO expression and cognitive decline in Alzheimer disease (AD) using [18F]FEPPA PET imaging. We integrated this imaging data with 12 comprehensive clinical measures to assess disease severity and progression in AD, mild cognitive impairment (MCI), and healthy controls (HC). Methods: A total of 39 participants, including 17 AD patients, 9 MCI patients, and 13 healthy controls, underwent [18F]FEPPA PET imaging and neuropsychological evaluations. Quantitative analysis was performed to determine the total distribution volume (VT) ratios in 8 brain regions, such as the frontal lobe, parietal lobe, and hippocampus. Cognitive function was assessed using a battery of tests, including the Mini-Mental State Examination (MMSE), Rey Auditory Verbal Learning Test (RAVLT), and Trail Making Test. Results: AD patients exhibited significantly elevated VT ratios in the frontal lobe, parietal lobe, and hippocampus compared with HC (P < 0.01). Notably, MCI patients had higher VT ratios than both HC and AD in the temporal and occipital lobes (P < 0.05), indicating early neuroinflammatory involvement. Moderate to strong correlations (R 2 values: 0.45–0.68) were observed between TSPO expression and cognitive performance. Conclusions: The findings of this study provide preliminary support for the use of [18F]FEPPA PET in assessing neuroinflammation related to cognitive decline in AD. Moreover, our results indicate that combining imaging techniques with neuropsychological assessments may offer a useful approach for monitoring disease progression and detecting early inflammatory changes in individuals with MCI.
- Open Access
- 1 June 2024
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 14 (6) , 4177-4188
Prognostic assessment of 18F-boronophenylalanine positron emission tomography (BPA-PET) in salvage boron neutron capture therapy for malignant brain tumors
Original Article Prognostic assessment of 18F-boronophenylalanine positron emission tomography (BPA-PET) in salvage boron neutron capture therapy for malignant brain tumors Ko-Han Lin, Yi-Wei Chen, Ling-Wei Wang, Yuh-Feng Wang, Lien-Hsin Hu, Chien Hsin Ting, Tse-Hao Lee, Jia-Cheng Lee, Nan-Jing Peng
- 1 June 2024
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 14 (6) , 4177-4188
Open AccessPrognostic assessment of 18F-boronophenylalanine positron emission tomography (BPA-PET) in salvage boron neutron capture therapy for malignant brain tumors
Original Article Prognostic assessment of 18F-boronophenylalanine positron emission tomography (BPA-PET) in salvage boron neutron capture therapy for malignant brain tumors Ko-Han Lin, Yi-Wei Chen, Ling-Wei Wang, Yuh-Feng Wang, Lien-Hsin Hu, Chien Hsin Ting, Tse-Hao Lee, Jia-Cheng Lee, Nan-Jing Peng
- Open Access
- 21 May 2024
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 87 (7) , 734-740
Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan
Background: Radium-223 dichloride (Ra-223) prolongs overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases. However, there is considerable variation in outcomes among individuals. We aimed to evaluate the prognostic determinants associated with patient survival following National Health Insurance (NHI) reimbursement for Ra-223 therapy in Taiwan. Methods: Patients with mCRPC who underwent Ra-223 treatment at Taipei Veterans General Hospital were retrospectively enrolled. Each intravenous Ra-223 dose was administered at 55 kBq/kg at 4-week intervals. Clinical outcomes were obtained from medical records; potential prognostic factors for survival were assessed. Kaplan-Meier analysis was used to generate cumulative survival curves; between-group differences were evaluated using the Chi-squared test. Statistical significance was set at p < 0.05. Results: Seventy-six patients underwent Ra-223 therapy; 62 patients received NHI reimbursement and the remainder self-paid. Fifty patients (65.8%) completed six cycles of treatment; 26 (34.2%) received 1 to 5 cycles. Mortality occurred in 47 patients. Factors significantly associated with survival included ≤five bone metastases (p = 0.0018), baseline prostate-specific antigen (PSA) ≤36 ng/mL (p = 0.0004), baseline alkaline phosphate (ALP) 12 g/dL (p = 0.0029). Patients who completed six cycles of treatment achieved significantly higher OS compared to those who did not (p < 0.0001). There has been a 4.4-fold increase in the number of patients since reimbursement began; there was no significant difference in OS between patients who received NHI reimbursement and those who self-paid. Conclusion: Administration of Ra-223 demonstrates considerable potential to extend the survival of patients with mCRPC. Survival outcomes may be influenced by various prognostic factors. However, no significant difference in OS was observed subsequent to reimbursement of Ra-223 therapy for mCRPC through the NHI system in Taiwan.
- 21 May 2024
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 87 (7) , 734-740
Open AccessSurvival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan
Background: Radium-223 dichloride (Ra-223) prolongs overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases. However, there is considerable variation in outcomes among individuals. We aimed to evaluate the prognostic determinants associated with patient survival following National Health Insurance (NHI) reimbursement for Ra-223 therapy in Taiwan. Methods: Patients with mCRPC who underwent Ra-223 treatment at Taipei Veterans General Hospital were retrospectively enrolled. Each intravenous Ra-223 dose was administered at 55 kBq/kg at 4-week intervals. Clinical outcomes were obtained from medical records; potential prognostic factors for survival were assessed. Kaplan-Meier analysis was used to generate cumulative survival curves; between-group differences were evaluated using the Chi-squared test. Statistical significance was set at p < 0.05. Results: Seventy-six patients underwent Ra-223 therapy; 62 patients received NHI reimbursement and the remainder self-paid. Fifty patients (65.8%) completed six cycles of treatment; 26 (34.2%) received 1 to 5 cycles. Mortality occurred in 47 patients. Factors significantly associated with survival included ≤five bone metastases (p = 0.0018), baseline prostate-specific antigen (PSA) ≤36 ng/mL (p = 0.0004), baseline alkaline phosphate (ALP) 12 g/dL (p = 0.0029). Patients who completed six cycles of treatment achieved significantly higher OS compared to those who did not (p < 0.0001). There has been a 4.4-fold increase in the number of patients since reimbursement began; there was no significant difference in OS between patients who received NHI reimbursement and those who self-paid. Conclusion: Administration of Ra-223 demonstrates considerable potential to extend the survival of patients with mCRPC. Survival outcomes may be influenced by various prognostic factors. However, no significant difference in OS was observed subsequent to reimbursement of Ra-223 therapy for mCRPC through the NHI system in Taiwan.
- 26 October 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (2) , 132-142
Comparison of the Detection Performance Between FAP and FDG PET/CT in Various Cancers
Purpose: 18F-FDG is the dominant radiotracer in oncology; however, it has limitations. Novel labeled fibroblast activation protein (FAP) radiotracers have been developed and published in several studies. Thus, this meta-analysis aimed to compare the detection rates (DRs) of FDG and FAP, based on previous studies from a systematic review. Methods: PubMed/MEDLINE and Cochrane library databases were used to perform a comprehensive and systematic search and are updated to April 30, 2022. The DR, relative risk, and the SUVmax were calculated between the FAP and FDG tracers. Finally, the sensitivity, specificity, diagnostic odds ratio, and summary receiver operating characteristic curve of FAP and FDG were analyzed using gold and reference standards. Results: Thirty studies (1170 patients) were included in the meta-analysis. The relative risks of FAP DR for the primary tumor, recurrent tumor, lymph node metastasis, and distant metastasis were FDG 1.06- to 3.00-fold per patient and per lesion. For the primary tumor, FAP uptake was most intense in pancreatic cancer, followed by head and neck, cervical, colorectal, lung, gastric, and hepatocellular carcinoma, and was higher than FDG except for urological system cancer. The sensitivity (0.84–0.98), diagnostic odds ratio (19.36–358.47), and summary receiver operating characteristic curve (0.94–0.99) of FAP based on patient and lesion were better for primary tumors, LN metastasis, and distant metastasis than FDG. Conclusions: Fibroblast activation protein is an extremely potential radiotracer to replace most of the use of FDG in oncology. It is noteworthy that the FAP tracers for primary tumors had low specificity despite excellent sensitivity and had lower uptake than FDG in urological system cancer. In addition, the difference in detection between FAP and FDG for LN metastasis could not be certain in sarcoma.
- 26 October 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 48 (2) , 132-142
Comparison of the Detection Performance Between FAP and FDG PET/CT in Various Cancers
Purpose: 18F-FDG is the dominant radiotracer in oncology; however, it has limitations. Novel labeled fibroblast activation protein (FAP) radiotracers have been developed and published in several studies. Thus, this meta-analysis aimed to compare the detection rates (DRs) of FDG and FAP, based on previous studies from a systematic review. Methods: PubMed/MEDLINE and Cochrane library databases were used to perform a comprehensive and systematic search and are updated to April 30, 2022. The DR, relative risk, and the SUVmax were calculated between the FAP and FDG tracers. Finally, the sensitivity, specificity, diagnostic odds ratio, and summary receiver operating characteristic curve of FAP and FDG were analyzed using gold and reference standards. Results: Thirty studies (1170 patients) were included in the meta-analysis. The relative risks of FAP DR for the primary tumor, recurrent tumor, lymph node metastasis, and distant metastasis were FDG 1.06- to 3.00-fold per patient and per lesion. For the primary tumor, FAP uptake was most intense in pancreatic cancer, followed by head and neck, cervical, colorectal, lung, gastric, and hepatocellular carcinoma, and was higher than FDG except for urological system cancer. The sensitivity (0.84–0.98), diagnostic odds ratio (19.36–358.47), and summary receiver operating characteristic curve (0.94–0.99) of FAP based on patient and lesion were better for primary tumors, LN metastasis, and distant metastasis than FDG. Conclusions: Fibroblast activation protein is an extremely potential radiotracer to replace most of the use of FDG in oncology. It is noteworthy that the FAP tracers for primary tumors had low specificity despite excellent sensitivity and had lower uptake than FDG in urological system cancer. In addition, the difference in detection between FAP and FDG for LN metastasis could not be certain in sarcoma.
- Open Access
- 24 January 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47 (3) , 201-208
99mTc-TRODAT-1 SPECT Revealed That Striatal Dopamine Transport Availability Significantly Decreases in Late Mid-Aged Healthy Taiwanese and Then Remains Stable
Objectives: Neuroimaging studies in the past 20 years have documented an age-related decline in striatal dopamine transporters (DATs), which is a marker of dopaminergic neurodegeneration; however, concerns about ethnic variations in the decline in DAT with age have not been addressed. The purpose of this study was to assess the rate of striatal DAT loss in healthy Taiwanese adults using kit-based 99mTc-TRODAT-1, a radioligand for DAT SPECT. Patients and Methods: Fifty healthy subjects (mean age ± SD, 63 ± 12 years; range, 30–80 years) were studied. 99mTc-TRODAT-1 was prepared from a lyophilized kit. Brain DAT SPECT imaging was acquired between 165 and 195 minutes postinjection (~740 MBq or 20 mCi) using a dual-head camera equipped with fan-beam collimators (Helix SPX; GE). Specific uptake in the striatum (ST), caudate nucleus (CA), and putamen (PU) were calculated from reconstructed transaxial slices at the level of maximal striatal activity. Occipital cortices were used as reference areas. Data were presented as specific binding ratios. Results: Age had a significant moderate to large negative effect on striatal DAT, which declined by −25.7% ± 6.10% between the ages of 30 and 80 years, equivalent to 6.4% loss per decade. The rates of decline in the CA and PU were 6.9% and 7.3% per decade, respectively. Conclusions: This study suggests ethnic variations may not significantly affect the age-related decline in DAT. The data generated in this study could also be used as a reference to estimate DAT loss/occupancy in patients with DAT-related diseases.
- 24 January 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47 (3) , 201-208
Open Access99mTc-TRODAT-1 SPECT Revealed That Striatal Dopamine Transport Availability Significantly Decreases in Late Mid-Aged Healthy Taiwanese and Then Remains Stable
Objectives: Neuroimaging studies in the past 20 years have documented an age-related decline in striatal dopamine transporters (DATs), which is a marker of dopaminergic neurodegeneration; however, concerns about ethnic variations in the decline in DAT with age have not been addressed. The purpose of this study was to assess the rate of striatal DAT loss in healthy Taiwanese adults using kit-based 99mTc-TRODAT-1, a radioligand for DAT SPECT. Patients and Methods: Fifty healthy subjects (mean age ± SD, 63 ± 12 years; range, 30–80 years) were studied. 99mTc-TRODAT-1 was prepared from a lyophilized kit. Brain DAT SPECT imaging was acquired between 165 and 195 minutes postinjection (~740 MBq or 20 mCi) using a dual-head camera equipped with fan-beam collimators (Helix SPX; GE). Specific uptake in the striatum (ST), caudate nucleus (CA), and putamen (PU) were calculated from reconstructed transaxial slices at the level of maximal striatal activity. Occipital cortices were used as reference areas. Data were presented as specific binding ratios. Results: Age had a significant moderate to large negative effect on striatal DAT, which declined by −25.7% ± 6.10% between the ages of 30 and 80 years, equivalent to 6.4% loss per decade. The rates of decline in the CA and PU were 6.9% and 7.3% per decade, respectively. Conclusions: This study suggests ethnic variations may not significantly affect the age-related decline in DAT. The data generated in this study could also be used as a reference to estimate DAT loss/occupancy in patients with DAT-related diseases.